AU2013370932B2 - Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy - Google Patents

Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy Download PDF

Info

Publication number
AU2013370932B2
AU2013370932B2 AU2013370932A AU2013370932A AU2013370932B2 AU 2013370932 B2 AU2013370932 B2 AU 2013370932B2 AU 2013370932 A AU2013370932 A AU 2013370932A AU 2013370932 A AU2013370932 A AU 2013370932A AU 2013370932 B2 AU2013370932 B2 AU 2013370932B2
Authority
AU
Australia
Prior art keywords
vaccine
cancer
subject
biological sample
mscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013370932A
Other languages
English (en)
Other versions
AU2013370932A1 (en
Inventor
Ross Arthur DAVEY
Graham Vesey
Christopher John WEIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northern Sydney Local Health District
Cell Ideas Pty Ltd
Original Assignee
Northern Sydney Local Health District
Cell Ideas Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012905669A external-priority patent/AU2012905669A0/en
Priority claimed from AU2013203806A external-priority patent/AU2013203806B2/en
Application filed by Northern Sydney Local Health District, Cell Ideas Pty Ltd filed Critical Northern Sydney Local Health District
Priority to AU2013370932A priority Critical patent/AU2013370932B2/en
Publication of AU2013370932A1 publication Critical patent/AU2013370932A1/en
Application granted granted Critical
Publication of AU2013370932B2 publication Critical patent/AU2013370932B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2013370932A 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy Ceased AU2013370932B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013370932A AU2013370932B2 (en) 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
AU2012905669A AU2012905669A0 (en) 2012-12-24 Vaccine booster
AU2012905667 2012-12-24
AU2012905667A AU2012905667A0 (en) 2012-12-24 Vaccines for treatment of cancer
AU2012905669 2012-12-24
AU2013203806A AU2013203806B2 (en) 2012-12-24 2013-04-11 Vaccines for the treatment or prevention of cancer
AU2013203806 2013-04-11
AU2013903592 2013-09-18
AU2013903592A AU2013903592A0 (en) 2013-09-18 Vaccines for the treatment or prevention of cancer
AU2013370932A AU2013370932B2 (en) 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
PCT/AU2013/001523 WO2014100857A1 (en) 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Publications (2)

Publication Number Publication Date
AU2013370932A1 AU2013370932A1 (en) 2015-07-09
AU2013370932B2 true AU2013370932B2 (en) 2019-02-21

Family

ID=53547734

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013370932A Ceased AU2013370932B2 (en) 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Country Status (7)

Country Link
US (2) US10357538B2 (enExample)
EP (2) EP3446708A1 (enExample)
JP (2) JP6286445B2 (enExample)
AU (1) AU2013370932B2 (enExample)
CA (1) CA2934958A1 (enExample)
NZ (1) NZ629700A (enExample)
WO (1) WO2014100857A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3446708A1 (en) * 2012-12-24 2019-02-27 Cell Ideas Pty Ltd. Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
SG11201806587RA (en) 2016-02-04 2018-09-27 Longeveron Llc Mesenchymal stem cells as vaccine adjuvants and methods for using the same
JP6971986B2 (ja) * 2016-04-01 2021-11-24 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
US11054389B2 (en) * 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015199A1 (en) * 1997-09-20 1999-04-01 Osiris Therapeutics, Inc. Antigen presenting mesenchymal stem cells
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US20110027311A1 (en) * 2009-07-30 2011-02-03 Healthbanks Biotech Co., Ltd. Combination of protein vaccine and mesenchymal stem cells for treating cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62221636A (ja) * 1986-03-20 1987-09-29 Chemo Sero Therapeut Res Inst Ｂ型肝炎ウイルス抗原蛋白の可溶化方法
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6379671B1 (en) * 1996-08-19 2002-04-30 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US20040076622A1 (en) * 2002-03-02 2004-04-22 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
AU2004268497A1 (en) * 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
AU2003903317A0 (en) 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
CN1887296B (zh) * 2006-07-31 2011-05-25 南京大学生物制药工程研究中心 一种诱导抗肿瘤免疫的方法及其在制药中的应用
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
KR20110038569A (ko) * 2009-10-08 2011-04-14 주식회사 알앤엘바이오 인간 유래 성체 줄기세포를 함유하는 항암용 조성물
JP2013510582A (ja) * 2009-11-12 2013-03-28 ザ テキサス エーアンドエム ユニバーシティー システム 間葉幹細胞の球状集合体
KR20120132183A (ko) * 2011-05-27 2012-12-05 포항공과대학교 산학협력단 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
SG10201606745XA (en) 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
EP3446708A1 (en) * 2012-12-24 2019-02-27 Cell Ideas Pty Ltd. Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015199A1 (en) * 1997-09-20 1999-04-01 Osiris Therapeutics, Inc. Antigen presenting mesenchymal stem cells
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US20110027311A1 (en) * 2009-07-30 2011-02-03 Healthbanks Biotech Co., Ltd. Combination of protein vaccine and mesenchymal stem cells for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUCEROVA L. et al., "Cytosine deaminase expressing human mesenchymal stem cells mediated tumor regression in melanoma bearing mice", The Journal of Gene Medicine, 2008, Vol. 10, No. 10, pages 1071-1082 *
SEO S.H. et al., "The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity", Gene Therapy, May 2011, Vol. 18, No. 5, pages 488-495 *
WEI, H-J. et al., "The Development of a Novel Cancer Immunotherapeutic Platform Using Tumor-targeting Mesenchymal Stem Cells and a Protein Vaccine", Molecular Therapy, December 2011, Vol. 19, No. 12, pages 2249-2257 *

Also Published As

Publication number Publication date
EP2934578A1 (en) 2015-10-28
AU2013370932A1 (en) 2015-07-09
EP2934578A4 (en) 2016-07-13
US10357538B2 (en) 2019-07-23
WO2014100857A1 (en) 2014-07-03
WO2014100857A8 (en) 2014-11-06
US20150343040A1 (en) 2015-12-03
WO2014100857A9 (en) 2015-07-09
CA2934958A1 (en) 2014-07-03
EP3446708A1 (en) 2019-02-27
JP2016505003A (ja) 2016-02-18
JP2018111695A (ja) 2018-07-19
US20190358291A1 (en) 2019-11-28
EP2934578B1 (en) 2018-11-21
JP6286445B2 (ja) 2018-02-28
NZ629700A (en) 2017-01-27

Similar Documents

Publication Publication Date Title
US20190358291A1 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
RU2766457C2 (ru) Способы и композиции для лечения рака с помощью антисмысла
JP6788663B2 (ja) 癌処置のための天然痘ワクチン
Muragaki et al. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma
JP2004521867A (ja) 免疫抑制された患者のためのワクチン免疫療法
Du et al. Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors
Mocan et al. RETRACTED ARTICLE: Effective colon cancer prophylaxis in mice using embryonic stem cells and carbon nanotubes
Hoover et al. N‐Dihydrogalactochitosan Drives Conventional and Alternative Activations of STING to Synergize Type I IFN and IL‐1β Productions for Antitumor Immunity.
Chen et al. Antigen-caged-adjuvant nanovaccines elicit potent humoral and cellular immune responses
KR20240009925A (ko) 암 치료에 있어서 수술전후기의 선천적 면역 프라이밍
CN119896727B (zh) CCR5hi固有免疫记忆细胞在制备治疗脓毒症免疫治疗药物中的应用
CN109891238A (zh) 免疫治疗剂的剂量确定
AU2013203806B2 (en) Vaccines for the treatment or prevention of cancer
WO2007043630A1 (ja) 上気道粘膜下に投与されるｎｋｔ細胞刺激剤
WO2014139456A1 (zh) 氢氧化铝在制备治疗肝癌药物中的应用
WO2024108955A1 (zh) 乙型肝炎疫苗
US20110236345A1 (en) Composition and methods for eliciting an immune response
He et al. Antitumor efficacy induced by a B16F10 tumor cell vaccine treated with mitoxantrone alone or in combination with reserpine and verapamil in mice
JP6329138B2 (ja) ペプチドカクテルワクチン
CN120676961A (zh) 基于γ-δT细胞细胞外囊泡的肿瘤疫苗的组合物和方法
WO2024210859A1 (en) Use of embryonated toxocara canis eggs inactivated by different methods as a drug candidate
WO2025217985A1 (zh) 葡萄糖-1-磷酸在治疗肿瘤中的用途
CN120392969A (zh) 免疫联合用药物及其在治疗肿瘤中的应用
Brown An empirical framework for combining surgery with immune therapy
BR102013023768A2 (pt) vacina terapêutica na imunoterapia da leishmaniose visceral humana e/ou canina

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired